CD19-targeted CAR-T has achieved unprecedented clinical response in leukemia and lymphoma, and now B-cell maturation antigen (BCMA)-targeted CAR-T is yielding remarkable results in patients with multiple myeloma (6, 7). Here, TNFRSF17 is linked to plasma cell myeloma.